Welcome to our dedicated page for MDTLL news (Ticker: MDTLL), a resource for investors and traders seeking the latest updates and insights on MDTLL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MDTLL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MDTLL's position in the market.
Infermedica has launched its Intake API, enhancing its capabilities in AI-driven patient intake workflows. This improvement aims to boost clinician efficiency and personalize patient experiences by facilitating the hassle-free transfer of data before medical consultations. The Intake tool is designed to reduce costs, decrease administrative burdens, and help alleviate clinician burnout by enabling better data collection and preparation for appointments. With a 95% engine-accuracy rate, Infermedica's platform has completed over 13 million health checks globally. The API is now available for health plans, insurers, and telemedicine providers, contributing to the company's vision of accessible healthcare.
Teva Pharmaceutical Industries Ltd. reported a net loss of $2.35 billion for 2022, with a diluted loss per share of $2.12. Total revenues for the year were $14.9 billion, a 6% decrease from 2021, attributed to lower sales of COPAXONE and respiratory products. For Q4 2022, revenues were $3.9 billion, while GAAP diluted EPS stood at $(1.10). The company anticipates revenues in 2023 to range between $14.8 - $15.4 billion, with adjusted EBITDA expected at $4.5 - $4.9 billion. Positive momentum was noted in innovative products like AUSTEDO and AJOVY, which drove significant growth.
Valbiotis has signed a research partnership with the MEDIS Unit from Clermont Auvergne University to develop the MIMETiv project, focusing on its plant-based active substances, TOTUM•070 and TOTUM•448. Funded partly by the French National Research Agency with €363,000, this initiative aims to create a comprehensive model of the human upper digestive tract by 2024. The model will yield proprietary data on the substances' effects on metabolism and microbiota, reinforcing Valbiotis' commitment to combating metabolic and cardiovascular diseases.
Teva Pharmaceutical Industries Ltd. reported Q3 2022 revenues of $3.6 billion, an 8% decline from Q3 2021. GAAP diluted EPS was $0.05, while non-GAAP EPS was $0.59. The company revised its 2022 revenue outlook to $14.8-$15.4 billion due to foreign exchange headwinds. AUSTEDO and AJOVY showed strong growth, with AUSTEDO's U.S. revenues increasing by 30%. However, revenues from generic products declined in North America, and the company faced significant foreign exchange impacts. Teva expects a non-GAAP tax rate of 12%-14% for 2022.
Teva Pharmaceutical Industries Ltd. has agreed in principle on the primary financial terms of a nationwide opioids settlement, revising its provision to reflect this. The company reported Q2 2022 revenues of $3.8 billion, with a GAAP diluted loss per share of $0.21 and a non-GAAP diluted EPS of $0.68. The 2022 revenue outlook has been revised down to $15.0 - $15.6 billion, mainly due to foreign exchange headwinds and increased competition for COPAXONE®, which is now expected to generate around $700 million. The company aims to finalize the settlement documentation soon.
